Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
0(0%)
Results Posted
114%(8 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_2
2
25%
Ph phase_3
6
75%

Phase Distribution

0

Early Stage

2

Mid Stage

6

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
2(25.0%)
Phase 3Large-scale testing
6(75.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(7)
Terminated(1)

Detailed Status

Completed7
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
87.5%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (25.0%)
Phase 36 (75.0%)

Trials by Status

completed788%
terminated113%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_2

A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor

NCT03312738
completedphase_3

Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy

NCT00790036
terminatedphase_2

Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC

NCT01379521
completedphase_3

Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

NCT00863655
completedphase_3

Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)

NCT00790400
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT03312738Phase 2

A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor

Completed
NCT00790036Phase 3

Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy

Completed
NCT01379521Phase 2

Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC

Terminated
NCT00863655Phase 3

Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

Completed
NCT00790400Phase 3

Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)

Completed
NCT01035229Phase 3

Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.

Completed
NCT00879333Phase 3

Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)

Completed
NCT00510068Phase 3

Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8